Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q7Z7L1

UPID:
SLN11_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q7Z7L1; E1P643; Q8N3S8; Q8N762; Q8TEE0

BACKGROUND:
Schlafen family member 11 plays a critical role in cellular defense mechanisms, acting as an inhibitor of DNA replication to trigger cell death upon DNA damage. This protein is crucial for maintaining genomic stability by preventing the proliferation of cells with compromised DNA replication. Beyond its role in genomic integrity, SLFN11 also exhibits potent antiviral activity, specifically targeting retrovirus protein synthesis, including that of HIV-1, by exploiting the viral codon bias towards A/T nucleotides.

THERAPEUTIC SIGNIFICANCE:
The exploration of Schlafen family member 11's functions offers a promising avenue for therapeutic intervention. Its dual role in promoting cell death in response to DNA damage and inhibiting retrovirus replication highlights its potential as a target for the development of novel therapies aimed at treating cancer and viral diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.